epileptic encephalopathy

Neurocrine's $50M bet on Idorsia drug flames out in second PhII
Endpoints
Wed, 12/7/22 - 09:58 am
Neurocrine
Idorsia
clinical trials
NBI-827104
epileptic encephalopathy